Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 1,700 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00. Following the sale, the executive vice president owned 109,504 shares of the company’s stock, valued at approximately $6,560,384.64. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $63.04, for a total value of $107,168.00.
• On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $64.85, for a total value of $110,245.00.

DexCom Price Performance

NASDAQ:DXCM traded up $1.86 during mid-day trading on Tuesday, reaching $66.95. The stock had a trading volume of 11,299,467 shares, compared to its average volume of 5,199,357. The firm has a 50 day moving average price of $63.35 and a two-hundred day moving average price of $65.83. The stock has a market capitalization of $25.83 billion, a P/E ratio of 28.61, a P/E/G ratio of 1.06 and a beta of 1.40. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. As a group, analysts expect that DexCom, Inc. will post 2.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent research reports. Truist Financial restated a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Canaccord Genuity Group set a $82.00 target price on DexCom and gave the stock a “buy” rating in a research report on Monday. Bank of America dropped their target price on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday. Mizuho set a $75.00 target price on DexCom in a research report on Friday, May 1st. Finally, TD Cowen decreased their price target on DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $82.21.

Hedge Funds Weigh In On DexCom

Large investors have recently bought and sold shares of the stock. Reflection Asset Management purchased a new position in DexCom in the 4th quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new position in DexCom in the 1st quarter worth approximately $25,000. CVA Family Office LLC increased its stake in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. MCF Advisors LLC purchased a new position in DexCom in the 4th quarter worth approximately $32,000. Finally, ORG Partners LLC increased its stake in DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.